Shingles Vaccine Linked to Lower Heart Attack & Stroke Risk
- A new global systematic literature review and meta-analysis reveals a statistically significant association between herpes zoster vaccination (shingles vaccine) and a reduced risk of both heart attack and...
- The study,the first of its kind to comprehensively assess this link,analyzed data from multiple studies comparing individuals who received the herpes zoster vaccine (either recombinant herpes zoster vaccine...
- In studies reporting absolute risk, the research indicated a difference of 1.2 to 2.2 fewer cardiovascular events per 1,000 person-years among vaccinated individuals.
“`html
Shingles Vaccine Linked to lower Risk of Heart Attack and stroke: A Global Meta-Analysis
Table of Contents
Published: August 28, 2025
What Happened?
A new global systematic literature review and meta-analysis reveals a statistically significant association between herpes zoster vaccination (shingles vaccine) and a reduced risk of both heart attack and stroke. the findings, presented at the 2025 European Society of Cardiology Congress in Madrid, Spain, suggest a potential protective effect of the vaccine on cardiovascular health.
Key Findings & Data
The study,the first of its kind to comprehensively assess this link,analyzed data from multiple studies comparing individuals who received the herpes zoster vaccine (either recombinant herpes zoster vaccine – RZV,or live attenuated zoster vaccine – ZVL) with those who did not.
| Age Group | Risk Reduction in Cardiovascular Events |
|---|---|
| ≥ 18 years | 18% |
| ≥ 50 years | 16% |
In studies reporting absolute risk, the research indicated a difference of 1.2 to 2.2 fewer cardiovascular events per 1,000 person-years among vaccinated individuals.
What Does This Meen?
While the study demonstrates a clear association, it does *not* prove causation. The observed reduction in cardiovascular events among those vaccinated against shingles is encouraging, but further research is crucial to determine if the vaccine itself is directly responsible for this protective effect. Several potential mechanisms are being explored, including the impact of the vaccine on inflammation and immune function.
Who is Affected?
These findings are relevant to a broad population, particularly adults aged 18 and older.Individuals at higher risk of cardiovascular disease, as well as those eligible for shingles vaccination, may benefit from understanding this potential added benefit. The current recommendations for shingles vaccination vary by region, but generally include adults aged 50 and older. This research may influence future vaccination guidelines.
Timeline of Research
- August 28, 2025: study findings released.
- August 30, 2025 (08:15 CEST): Presentation at the 2025 European Society of Cardiology Congress in Madrid, Spain.
- Ongoing: Further research studies are planned to investigate the causal relationship between herpes zoster vaccination and cardiovascular health.
Frequently Asked Questions (FAQs)
- Does this mean the shingles vaccine prevents heart attacks and strokes?
- Not necessarily. The study shows an association, but more research is needed to prove a causal link. it’s possible other factors contribute to the observed reduction in cardiovascular events.
- Should I get the shingles vaccine if I’m concerned about heart health?
- Discuss this with your doctor. The shingles vaccine is primarily recommended for preventing shingles, but this new research adds another layer to the conversation. Your doctor can assess your individual risk factors and advise you accordingly.
- What types of shingles vaccines were included in the study?
- Both the recombinant herpes zoster vaccine (RZV) and the live attenuated zoster vaccine (ZVL) were included in the analysis.
Next Steps & Further Research
Researchers are planning additional studies to investigate the underlying mechanisms driving this association.These studies will likely involve larger cohorts,